SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Michel, M.S., Vervenne, W., Santis, M. de, Weikersthal, L.F. von, Goebell, P.J., Lerchenmueller, C., Zimmermann, U., Bos, M.M.E.M., Freier, W., Schirrmacher-Memmel, S., Staehler, M.D., Pahernik, S., Los, M., Schenck, M., Flörcken, A., Arkel, C.V., Hauswald, K., Indorf, M., Gottstein, D., Eichelberg, C., 2014.

J Clin Oncol 32(suppl 4; abstr 393). doi: 10.1200/jco.2014.32.4_suppl.393

Studie: RCC-SWITCH; Indikation: Nierenzellkarzinom; Jahr: 2014; Veranstaltung: GCS (ASCO); Journal: Journal of Clinical Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com